Timing of Dynamic NT-proBNP and hs-cTnT Response to Exercise Challenge in Asymptomatic Children with Moderate Aortic Valve Regurgitation or Moderate Aortic Valve Stenosis

详细信息    查看全文

• 作者：Wadi Mawad ; Sylvia Abadir ; Anne Fournier ; Jean-Luc Bigras…
• 关键词：Aortic regurgitation ; Aortic stenosis ; Aortic valve disease ; Biomarker ; NT ; proBNP ; High ; sensitivity cardiac troponin T ; hs ; cTnT ; Treadmill testing
• 刊名：Pediatric Cardiology
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：36
• 期：8
• 页码：1735-1741
• 全文大小：596 KB
• 参考文献：1.Azevedo CF, Nigri M, Higuchi ML et al (2010) Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol 56:278-87. doi:10.-016/?j.?jacc.-009.-2.-74 CrossRef PubMed
  2.Bergler-Klein J, Gy?ngy?si M, Maurer G (2014) The role of biomarkers in valvular heart disease: focus on natriuretic peptides. Can J Cardiol 30:1027-034. doi:10.-016/?j.?cjca.-014.-7.-14 CrossRef PubMed
  3.Beroukhim RS, Graham DA, Margossian R et al (2010) An echocardiographic model predicting severity of aortic regurgitation in congenital heart disease. Circ Cardiovasc Imaging 3:542-49. doi:10.-161/?CIRCIMAGING.-10.-57175 CrossRef PubMed
  4.Bonow RO, Carabello BA, Chatterjee K et al (2006) ACC/AHA 2006 practice guidelines for the management of patients with valvular heart disease: executive summary. J Am Coll Cardiol 48:598-75. doi:10.-016/?j.?jacc.-006.-5.-30 CrossRef
  5.Capoulade R, Magne J, Dulgheru R et al (2014) Prognostic value of plasma B-type natriuretic peptide levels after exercise in patients with severe asymptomatic aortic stenosis. Heart 100:1606-612. doi:10.-136/?heartjnl-2014-305729 CrossRef PubMed
  6.Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R (2004) Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 6:365-68CrossRef PubMed
  7.Dahdah N, Siles A, Fournier A et al (2009) Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 30:810-17CrossRef PubMed
  8.de Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. Lancet 362:316-22. doi:10.-016/?S0140-6736(03)13976-1 CrossRef PubMed
  9.Lindahl B, Venge P, James S (2010) The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes. Am Heart J 160:224-29CrossRef PubMed
  10.Lopez L, Colan SD, Frommelt PC, Ensing GJ, Kendall K, Younoszai AK et al (2010) Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr 23:465-95CrossRef PubMed
  11.Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M (1998) Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135:825-32CrossRef PubMed
  12.Marcus KA, Mavinkurve-Groothuis AMC, Barends M et al (2011) Reference values for myocardial two-dimensional strain echocardiography in a healthy pediatric and young adult cohort. J Am Soc Echocardiogr 24:625-36. doi:10.-016/?j.?echo.-011.-1.-21 CrossRef PubMed
  13.Mir TS, Haddad M, Laer S (2006) N-Terminal pro
  ain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clin Chem Lab Med 44:80-5PubMed
  14.Mischie AN, Andrei CL, Sinescu C (2013) Viewpoint: the ENIGMAS trial—When should we treat patients with moderate aortic stenosis? Echocardiography 30:599-15. doi:10.-111/?echo.-2080 CrossRef PubMed
  15.Monin J-L, Lancellotti P, Monchi M et al (2009) Risk score for predicting outcome in patients with asymptomatic aortic stenosis. Circulation 120:69-5. doi:10.-161/?CIRCULATIONAHA.-08.-08857 CrossRef PubMed
  16.Nakagawa O, Ogawa Y, Itoh H et al (1995) Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency-cardiac hormone against ventricular overload. J Clin Invest 96:1280-287PubMedCentral CrossRef PubMed
  17.Nishimura RA, Otto CM, Bonow RO et al (2014) 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:e57–e185. doi:10.-016/?j.?jacc.-014.-2.-36 CrossRef PubMed
  18.Otto CM (2004) Aortic stenosis: even mild disease is significant. Eur Heart J 25:185-87CrossRef PubMed
  19.Otto CM, Burwash IG, Legget ME et al (1997) Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 95:2262-270CrossRef PubMed
  20.Pellikka PA, Sarano ME, Nishimura RA et al (2005) Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 111:3290-295. doi:10.-161/?CIRCULATIONAHA.-04.-95903 CrossRef PubMed
  21.Pizarro R, Bazzino OO, Oberti PF et al (2011) Prospective validation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic patients with chr
• 作者单位：Wadi Mawad (1)
  Sylvia Abadir (1)
  Anne Fournier (1)
  Jean-Luc Bigras (1)
  Daniel Curnier (2)
  Lyes Kadem (3)
  Nagib Dahdah (1)
  
  1. Division of Pediatric Cardiology, CHU Sainte-Justine, University of Montreal, 3175, Cote Sainte-Catherine, Montréal, QC, H3T 1C5, Canada
  2. Department of Kinesiology, University of Montréal, Montréal, Canada
  3. Mechanical and Industrial Engineering Department, Concordia University, Montréal, QC, Canada
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Cardiology
  Cardiac Surgery
  Vascular Surgery
  
• 出版者：Springer New York
• ISSN：1432-1971

文摘

Patients with congenital aortic valve stenosis (AVS) can remain asymptomatic but may develop progressive and often underestimated exercise intolerance. The risk of increased left ventricular (LV) wall stress, irreversible myocardial fibrosis and sudden death in untreated patients warrants earlier intervention. The timing for curative therapy for severe AVS is clear, but optimal timing for moderate stenosis (modAS) is unknown. AVS often coexists with aortic regurgitation, which adds a volume overload to an already pressure-overloaded LV, adding an additional challenge to the estimation of disease severity. We investigated the possible value of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) upon treadmill exercise challenge in children with asymptomatic modAS versus moderate regurgitation (modAR). The aim was to determine optimal timing of peak biochemical response. Blood samples were obtained at rest, and then at 20, 40 and 60 min after peak exercise comparing modAS and modAR to healthy controls. Exercise performance was equivalent in all groups, with no difference for biomarker levels at rest. The increase in NT-proBNP was significant in modAR at 40 min (99.2 ± 48.6 ng/L; p = 0.04) and 60 min into recovery (100.0 ± 53.7 ng/L; p = 0.01), but not in modAS. The increase in hs-cTnT was significant only at 60 min into recovery for modAS and modAR. NT-proBNP and hs-cTnT following exercise challenge are possible discriminant biomarkers of modAR from modAS and controls at 60 min into recovery despite comparable exercise performance. This offers a promising avenue for future stratification of aortic valve disease and optimal timing of intervention. Keywords Aortic regurgitation Aortic stenosis Aortic valve disease Biomarker NT-proBNP High-sensitivity cardiac troponin T hs-cTnT Treadmill testing